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Background: Preventive measures need to be implemented to lower the incidence of osteoporotic fractures. Osteoporotic frac-
tures increase morbidity and mortality as well as impose a socioeconomic burden; however, current research is limited to the ad-
ministration rates of osteoporosis drugs for Korean postmenopausal females. 
Methods: This study represents a nationwide, observational, and cross-sectional survey that investigates the administration rates 
of osteoporosis drugs based upon a bone mineral density (BMD) test performed on Korean postmenopausal patients who visited 
outpatient orthopedic clinics. BMD test results were examined in postmenopausal female patients (50 to 80 years of age); subse-
quently, the patients were classified into an osteoporosis group, osteopenia group, and normal group. The administration rates of 
osteoporosis drugs and bisphosphonates were then analyzed. The osteoporosis group was subdivided into a T-score less than −3.0 
group and a T-score between −3.0 and −2.5 group that were separately analyzed.
Results: Based on the lumbar spine BMD, the rate of administration of osteoporosis drugs in the osteoporosis group was 42.1%, 
which was significantly higher compared to the osteopenia group or normal group. A significantly low bone mineral density was 
observed in patients who were administered bisphosphonates. Based on the lumbar spine BMD, the administration rate of osteo-
porosis drugs in the group with a T-score between −3.0 and −2.5 (34.2%) was significantly lower than the group with a T-score 
less that −3.0 (46.2%). The bisphosphonate administration rate was also significantly low; however, the administration rate for 
osteoporosis drugs was significantly lower than that of the osteopenia group. 
Conclusions: Only about 40% of Korean postmenopausal female patients with osteoporosis were administered osteoporosis 
drugs. The administration rate in patients with a T-score between −3.0 and −2.5 was particularly low and active treatment to pre-
vent osteoporotic fractures is required in this group. 
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Osteoporosis increases the fracture risk due to the reduc-
tion of bone strengh and bone mineral density (BMD) 
as well as the deterioration of the microarchitecture.1) 
Osteoporosis is asymptomatic unless fractures occur, and 
patients with osteoporosis do not realize the necessity 
of treatment or the adverse effects of neglecting treat-
ment if the BMD is not regularly monitored. Fractures 
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affect patient morbility and mortality; in addition, the 
socioeconomic costs of treatment increase significantly.2,3) 
The number of patients in Korea with osteoporosis has 
increased due to an aging population with a concomitant 
increase in the rate of osteoporotic fractures. Active pre-
vention and treatment are required to treat osteoporosis.
The most commonly prescribed medications for 
osteoporosis in Korea are bone resorption inhibitors (oral 
bisphosphonate/intravenous bisphosphonate, selective 
estrogen receptor modulator [SERM], and calcitonin); in 
addition, parathyroid hormone (a bone formation accel-
erator) is also prescribed. Calcium and vitamin D are also 
recommended as supplements. In Korea, insurance cover-
age is provided for bisphosphonates, SERM, and calcitonin 
prescriptions based upon the results of a BMD test using 
dual energy X-ray absorptiometry (DXA). Subsequently, 
the insurance benefit allowance criteria may influence the 
prescription of medications for osteoporosis.
Osteoporosis is defined by the World Health Orga-
nization (WHO) as a T-score −2.5 or lower based on the 
results of the DXA. Osteopenia is defined as a T-score over 
−2.5 and less than −1.0, and a T-score that exceeds −1.0 
is considered normal. However, until 2011, the National 
Health Insurance Service (NHIS) criteria for osteoporosis 
drugs in Korea covered only osteoporosis patients with a 
T-score less than −3.0; subsequently, NHIS insurance ben-
efits for osteoporosis drugs were unavailable to patients 
whose T-score exceeded −3.0 and was less than −2.5. Pa-
tients can not purchase the osteoprosis drug without the 
prescription of a medical doctor. For patients with osteo-
porosis whose T-score exceeds −3.0 and is less than −2.5, 
doctors prescribe the osteoprosis drug that is covered by 
insurance.
The objectives of this study were: (1) to investigate 
the administration rate and methods of osteoporosis drugs 
via nationwide, observational, and cross-sectional surveys 
based on a T-score computed from the DXA in patients 
who visited outpatient orthopedic clinics; and (2) to evalu-
ate the differences in the administration of osteoporosis 
drugs between osteoporosis patients with a T-score under 
−3.0 who qualified for the insurance benefit criteria in 
2011 and the patients with a T-score over −3.0 and under 
−2.5 who did not meet the insurance benefit criteria. 
 METHODS
Materials
In this study, nationwide, observational, and cross-sectional 
surveys were conducted on Korean postmenopausal pa-
tients who visited the orthopedics outpatient clinics of 62 
Korean general hospitals and clinics in 2011. The number of 
subjects was calculated assuming a 26% prevalence of osteo-
porotic compression vertebral fractures and 5% precision. 
The target subjects were 1,183 with a 95% confidence inter-
val; subsequently, a total of 1,281 subjects were included in 
this study as final test subjects. To correct for regional dif-
ferences among regions, the regional distribution of females 
older than 50 years old was confirmed utilizing the data 
provided by the Korea National Statistical Office in 2005. It 
was divided into a total of 4 regions that include the Seoul 
Metropolitan, Central, Youngnam, and Honam areas, with 
the same proportion of patients recruited from each region. 
The hospital obtained prior approval from the Institutional 
Review Boards based upon the Declaration of Helsinki for 
this study; subsequently, written informed consent was ob-
tained from all participants.
Female patients (50 to 80 years old) diagnosed as 
menopausal were selected from the patients who visited 
the orthopedics outpatient clinics. The subjects excluded 
from this study included (1) subjects without a diagnosis 
of menopause; (2) subjects who had high-energy injuries 
(including car accidents and falls) within the previous 
3 months; (3) subjects who experienced nonvertebral 
fractures within the previous 6 months; (4) subjects lack-
ing sufficient cognitive ability (based on the discretion of 
researchers); (5) cases where a normal readout was not 
possible in more than 2 segments due to fractures between 
the 1st and 4th lumbar spine vertebrae or instrumentation; 
and (6) cases where a BMD test could not be performed 
on both sides of the femur because of femoral fractures or 
instrumentation. 
Methods
Bone mineral density 
The DXA was used to measure the BMD of the lumbar 
spine, femoral neck, and total hip. If available, the data 
was replaced with the measurements from three months 
prior. Each patient was scanned under the examination 
guidelines from the manufacturer of the bone mineral 
densitometer. The lumbar spine (between the 1st and 
4th vertebrae) was measured and cases with fractures or 
instrumentation present in that range were excluded; sub-
sequently, the remaining measurements were averaged to 
calculate the lumbar spine averages. The data of the non-
surgical side was applied if there was a surgical history in 
the femoral neck and total hip. 
Correlation between the BMD and osteoporosis treatments
The administration rate of osteoporosis drugs was evalu-
ated based on the normal group, osteopenia group, os-
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teoporosis group (T-score ≥ −1.0, −2.5 < T-score < −1.0, 
and T-score ≤ −2.5), and combined group (T-score < 
−1.0). Then, the BMD of the patients (with and without 
bisphosphonate prescriptions) was compared regarding 
the lumbar spine, femoral neck, and total hip. The admin-
istration rates of osteoporosis drugs and bisphosphonates 
in the T-score ≤ −3.0 group and the −3.0 < T-score ≤ −2.5 
group were evaluated after subdividing the current insur-
ance benefit criteria for the osteoporosis group (T-score 
−3.0). The administration rates of osteoporosis drugs and 
bisphosphonates in the −3.0 < T-score ≤ −2.5 group and 
−2.5 < T-score < −1 group were investigated as well. 
Statistical Analysis
The statistical analysis of the administration rate of os-
teoporosis drugs among the groups utilized the Cochran-
Armitage trend test. Student’s t-test analyzed the BMD of 
patients with and without bisphosphonate administration. 
The chi-square test compared the administration rates of 
osteoporosis drugs and bisphosphonates between the T-
score ≤ −3.0 group and the −3.0 < T-score ≤ 2.5 group as 
well as between the −3.0 < T-score ≤ −2.5 group and the 
−2.5 < T-score < −1 group. 
RESULTS
Of 1,225 patients, the number of patients who were ad-
ministered bisphosphonates was 292 subjects (SERM 
dose, 11 subjects; calcitonin, 1 subject; and parathyroid 
hormone, 1 subject). Based on the lumbar spine T-score, 
the administration rate of osteoporosis drugs was 42.1% 
in the osteoporosis group, 24.4% in the osteopenia group, 
and 10.4% in the normal group. The administration rate 
for bisphosphonates was 38.4% in the osteoporosis group, 
18.8% in the osteopenia group, and 7.7% in the normal 
group, showing significant differences among the groups (p 
< 0.0001). The administration rate of osteoporosis drugs 
as well as bisphosphonates was significantly higher in the 
osteoporosis group compared to the osteopenia group 
and normal group (p < 0.001). The prescription rate for 
osteoporosis drugs and bisphosphonates was significantly 
higher for the osteopenia group versus the normal group 
(p < 0.001) (Table 1). Based on the femoral neck T-score, 
the administration rate of osteoporosis drugs and bisphos-
phonates in the osteoporosis group was 42.8% and 38.9%, 
respectively. Based on the total hip T-score, the adminis-
tration rate for osteoporosis drugs and bisphosphonates in 
the osteoporosis group was 37.4% and 36.4%, respectively. 
The administration rate for osteoporosis drugs (p < 0.001) 
and bisphosphonates (p < 0.001) in the osteoporosis group 
Table 1. Osteoporosis Treatment with Medication according to T-score
Location T-score Total
Osteoporosis drug treatment Bisphosphonate treatment
No. (%) p-value* No. (%) p-value*
Lumbar spine T ≤ −2.5 466 196 (42.1) < 0.001†, < 0.001‡ 179 (38.4) < 0.001†, < 0.001‡
−2.5 < T < −1.0 463 113 (24.4) < 0.001§ 87 (18.8) < 0.001§
T ≥ −1.0 324 36 (10.4) - 25 (7.7) -
p-value∥ <0.0001 < 0.0001
Femoral neck T ≤ −2.5 283 121 (42.8) 0.001†, < 0.001‡ 110 (38.9) < 0.001†, < 0.001‡
−2.5 < T < −1.0 551 160 (29.0) < 0.001§ 130 (23.6) < 0.001§
T ≥ −1.0 381 60 (15.7) - 48 (12.6) -
p-value∥ <0.0001 < 0.0001
Total hip T ≤ −2.5 195 73 (37.4) 0.468†, < 0.001‡ 71 (36.4) 0.06†, < 0.001‡
−2.5 < T < −1.0 491 166 (33.8)) < 0.001§ 136 (27.7) < 0.001§
T ≥ −1.0 470 75 (16.0) - 57 (12.1) -
p-value∥ <0.0001 < 0.0001
*p-value by post-hoc analysis. †p-value by chi-square test between T ≤ −2.5 and −2.5 < T < −1.0. ‡p-value by chi-square test between T ≤ −2.5 and T ≥ −1.0. 
§p-value by chi-square test between −2.5 < T < −1.0 and T ≥ −1.0. ∥p-value by chi-square test among 3 groups.
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was significantly higher compared to the osteopenia group 
and normal group according to the T-scores for the femo-
ral neck and total hip. The osteopenia group was adminis-
tered osteoporosis drugs (p < 0.001) and bisphosphonates 
(p < 0.001) at a significantly higher rate than the normal 
group.
BMD in Patients with Bisphosphonate Administration
Based on the lumbar spine T-score, the osteoporosis 
patients who were administered bisphosphonates had a 
significantly lower BMD (0.703 g/cm2) than patients not 
administered bisphosphonates (0.738 g/cm2; p = 0.0023). 
The BMD of the femoral neck and total hip was lower in 
patients with bisphosphonate administration compared 
to patients without prescriptions; however, there was no 
statistically significant difference observed (Table 2). In 
the osteopenia group, statistically significant differences 
were not found in the BMD of the lumbar spine, femoral 
neck, and total hip between the patients with and with-
out bisphosphonate administration. In the analysis that 
combined the osteoporosis group and osteopenia group, 
the BMD of the lumbar spine was 0.765 g/cm2, that of the 
femoral neck 0.655 g/cm2, and that of the total hip 0.706 g/
cm2 in patients with bisphosphonate administration. These 
were significantly lower than the BMD in patients without 
bisphosphonate administration, who had a lumbar spine 
BMD of 0.841 g/cm2, femoral neck BMD of 0.690 g/cm2, 
and a total hip BMD of 0.747 g/cm2 (p < 0.0001, 0.0026, 
and 0.0002, respectively).
Administration Rate of Osteoporosis Drugs in the −3.0 
< T-score ≤ −2.5 Group 
Regarding the lumbar spine, 46.2% of the osteoporosis 
drugs and 43.3% of bisphosphonates were administered in 
the T-score ≤ −3.0 group; these administration rates were 
significantly higher compared to the −3.0 < T-score ≤ −2.5 
group that showed an administration rate of 34.2% for os-
teoporosis drugs and 29.2% for bisphosphonates (p-values 
equal to 0.012 and 0.0029, respectively) (Table 3). How-
ever, based on the femoral neck and total hip, there was no 
statistically significant difference observed in the admin-
istration rate for osteoporosis drugs and bisphosphonate 
between the T-score ≤ −3.0 group and −3.0 < T-score ≤ 
−2.5 group.
With regards to the lumbar spine and femoral 
neck, the −3.0 < T-score ≤ −2.5 group was administered 
osteoporosis drugs (p-values equal to 0.0016 and 0.0002, 
respectively) and bisphosphonates (p -values equal to 
0.0056 and 0.0004, respectively) at a significantly higher 
rate compared to the −2.5 < T-score < −1 group (Table 4). 
However, regarding the total hip, significant differences 
were not present in the administration rate of osteoporosis 
Table 2. Bone Mineral Density in Patients with Bisphosphonate Treatment 
Variable
Lumbar spine BMD Femoral neck BMD Total hip BMD
No treatment BP treatment No treatment BP treatment No treatment BP treatment
Osteoporosis group
    No. 342 204 336 204 317 182
    Mean ± standard deviation 0.738 ± 0.144 0.703 ± 0.122 0.620 ± 0.213 0.613 ± 0.155 0.658 ± 0.141 0.666 ± 0.123
    p-value* 0.0023 0.6724 0.5038
Osteopenia group
    No. 395 79 394 78 366 74
    Mean ± standard deviation 0.930 ± 0.116 0.925 ± 0112 0.751 ± 0.151 0.762 ± 0.116 0.825 ± 0.197 0.803 ± 0.113
    p-value* 0.7286 0.4434 0.1948
Combined group of osteoporosis and osteopenia
    No. 737 283 730 282 683 256
    Mean ± standard deviation 0.841 ± 0.161 0.765 ± 0.155 0.690 ± 0.193 0.655 ± 0.159 0.747 ± 0.192 0.706 ± 0.135
    p-value* <0.0001 0.0026 0.0002
BMD: bone mineral density, BP: bisphosphonate.
*p-value by t-test.
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drugs and bisphosphonates between the −3.0 < T-score ≤ 
−2.5 group and −2.5 < T-score < −1 group. 
 DISCUSSION
The progressive loss of bone mass remains asymptomatic 
until fractures occur; therefore, many patients with osteo-
porosis do not realize the need for treatment or the serious 
consequences. In the case of vertebral fractures, the risk 
of further fractures increases dramatically after an initial 
fracture;4,5) in addition, there is an increase in associated 
kyphotic deformity of the spine, pain, respiratory complica-
tions, and mortality.2,6,7) The 1 year mortality rate for hip 
fractures is around 20%;8,9) subsequently, the prevention of 
hip fractures is very important. The mortality and signifi-
cance of osteoporotic vertebral fractures is generally under-
estimated because the mortality rate after vertebral fractures 
is reported to be higher than that of hip fractures.10) There-
fore, the active prevention of osteoporotic vertebral fractures 
(especially in relatively high-risk groups) is an excellent way 
to lower the opportunity costs of morbidity due to fractures 
as well as reduce mortality rates.
This study shows that the administration rate of 
osteoporosis drugs in the osteoporosis group was higher 
than that of the osteopenia group or normal group; in ad-
dition, the administration rate of osteoporosis drugs in 
the osteopenia group was higher compared to the normal 
group. The administration rate increased as the BMD de-
creased; however, the administration rate of osteoporosis 
drugs in the osteoporosis group with a T-score between 
−2.5 and −3.0 was significantly lower than patients with a 
T-score less than −3.0. This may be because prescriptions 
were focused on patients with severe osteoporosis and the 
NHIS insurance benefits regarding osteoporosis drugs 
were applied from a T-score less than −3.0 when this study 
was performed in 2011. Therefore, relatively fewer osteo-
porosis drug prescriptions were administered to osteopo-
rosis patients with a T-score greater than −3.0. The results 
Table 3. Administration Rates of Osteoporosis Drugs and Bisphosphonates in T-score ≤ −3.0 Group and −3.0 < T-score ≤ −2.5 Group 
T-score Total
Osteoporosis medication Bisphosphonate treatment
No. (%) p-value* No. (%) p-value*
L-spine −3 < T ≤ −2.5 161 55 (34.2) 0.012 47 (29.2) 0.0029
T ≤ −3.0 305 141 (46.2) 132 (43.3)
Femoral neck −3 < T ≤ −2.5 122 57 (46.7) 0.241 48 (39.3) 0.887
T ≤ −3.0 161 64 (39.8) 62 (38.5)
Total hip −3 < T ≤ −2.5 74 23 (31.1) 0.152 22 (29.7) 0.130
T ≤ −3.0 121 50 (41.3) 49 (40.5)
*p-value by chi-square test.
Table 4. Administration Rates of Osteoporosis Drugs and Bisphosphonates in 3.0 < T-score ≤ −2.5 Group and −2.5 < T-score < −1 Group 
T-score No.
Osteoporosis medication Bisphosphonate treatment
No. (%) p-value No. (%) p-value
L-spine −3 < T ≤ −2.5 161 55 (34.2) 0.016 47 (29.2) 0.0056
−2.5 < T < −1 463 113 (24.4) 87 (18.8)
Femoral neck −3 < T ≤ −2.5 122 57 (46.7) 0.0002 48 (39.3) 0.0004
−2.5 < T < −1 551 160 (29.0) 130 (23.6)
Total hip −3 < T ≤ −2.5 74 23 (31.1) 0.64 22 (29.7) 0.717
−2.5 < T < −1 491 166 (33.8) 136 (27.7)
*p-value by the chi-square test.
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imply that a lack of rationale (in terms of medical per-
spectives) was arbitrarily changed for administrative con-
venience and applied to the NHIS insurance application 
criteria; subsequently, medical prescription patterns were 
significantly altered. Cases with prolonged prescription 
patterns are expected to increase the fracture risk for high-
risk patients who require measures to prevent osteoporosis 
related fractures. The prevalence of osteoporotic fractures 
in Asia has rapidly increased.11,12) The percentage of the 
elderly in the population has increased in Korea along 
with the prevalence of osteoporotic fractures and the sub-
sequently increased socioeconomic burden. More active 
treatment is required to prevent osteoporotic fractures.
It was observed in the present study that bisphos-
phonates were most frequently administered to postmeno-
pausal females who visited outpatient orthopedic clinics; 
however, SERM was rarely prescribed and this may be 
because SERM is unfamiliar to orthopedists (even though 
it is not a hormone). The administration rate for bisphos-
phonates in the group with a T-score between −2.5 and 
−3.0 was significantly lower than the group with a T-score 
under −3.0; this indicated that it was influenced by the 
NHIS insurance benefit application criteria. 
The approximate administration rate of 40% for os-
teoporosis drugs was exhibited in postmenopausal patients 
with osteoporosis who visited orthopedic outpatient clin-
ics. Bisphosphonates were the most widely administered 
osteoporosis drug. The administration rate increased with 
a decrease in the BMD; however, patients with a T-score 
between −3.0 and −2.5 showed a significantly lower ad-
ministration rate compared to patients with a T-score less 
than −3.0. In conclusion, active treatment is recommended 
for osteoporosis patients with a high-risk of osteoporotic 
fractures.
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